Hal Barron
President Research And Development at GSK, former president of research and development at Calico and incoming CEO at Altos Labs
Barron will step down from GSK effective August 2022 to join Altos Labs as CEO.
Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He was also appointed to the GSK Board of Directors as an Executive Director and member of the Science Committee.
Hal is responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is a member of the Corporate Executive Team.
Prior to joining GSK in 2018, Hal was President, R&D at Calico (California Life Company). Prior to this, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Visit website: https://www.gsk.com/en-gb/about-us/board-of-directors/dr-hal-barron/
See also: 
Altos Labs
- Biotechnology company focused on cellular rejuvenation programming
Details last updated 27-Jan-2021
Hal Barron is also referenced in the following:
BSRA Annual Scientific Meeting 2023
06-Sep-2023 to 08-Sep-2023
A compelling lineup of speakers from all areas of the biology of ageing
Hal Barron News
Altos Labs comes out of stealth with $3 billion of capital
Genetic Engineering & Biotechnology News (GEN) - 19-Jan-2022
Huge backing that cellular reprogramming can have a significant impact on health and ageing
Read more...Broad Institute and Calico collaboration to find therapeutic approaches to diseases of aging
Calico - 17-Mar-2015
Calico is a Google-founded R&D company whose mission is to harness advanced technologies to incre...
Read more...
